Log In
Print
BCIQ
Print
Print this Print this
 

KRN23, UX023

  Manage Alerts
Collapse Summary General Information
Company Kyowa Hakko Kirin Co. Ltd.
DescriptionRecombinant human IgG1 mAb against fibroblast growth factor 23 (FGF23)
Molecular Target Fibroblast growth factor 23 (FGF23)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I/II
Standard Indication Musculoskeletal (unspecified)
Indication DetailsTreat X-linked hypophosphatemia (XLH)
Regulatory Designation

Partner

Ultragenyx Pharmaceutical Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today